BioVentrix has raised $21.8 million in a round of equity financing, according to a recently posed SEC filing.
The company is looking to bring in an additional $18.2 million in the round, which would bring the total raised up to $40 million.
A total of 158 unnamed investors joined the offering, with the first date of sale noted as having occurred on August 25, 2017, according to the filing.
The offering included $3.2 million in sales commissions, according to the filing. BioVentrix said that the placement agent also received warrants to purchase Series A-1 preferred stock equal to 10% of the number of shares of common stock the notes are convertible into at an exercise price of $7.50 per share.
In February, BioVentrix said that it won renewed German reimbursement for its Revivent TC transcatheter ventricular enhancement system.